Iteos

Iteos company information, Employees & Contact Information

Explore related pages

Related company profiles:

At Iteos, we not only create employees but also technicians, designers, developers, and engineers. Our areas of competence include Business consulting, CXO advisory, Outsourcing, Financial advice and other related services.  Expertise in cutting-edge technology, such as SAP, Microsoft, and Oracle, to boost the value of your organization. ITeos strives to provide customers valuable amenities. Mission : To bring best practice in IT & enables services, value service through innovation, empower stakeholders with diversity and inclusion. Vision : To bring inspiration and innovation through information and technology  services to inspire and innovate the world.

Company Details

Employees
45
Founded
-
Address
E207, Hustlehub Tech Park,27th Main,hsr Layout Sector-I,india
Industry
It Services And It Consulting
NAICS
Computer Systems Design and Related Services
Other Computer Related Services
HQ
Bangalore, Karnataka
Looking for a particular Iteos employee's phone or email?

Iteos Questions

News

Cancer drugmaker iTeos to shut down - BioPharma Dive

Cancer drugmaker iTeos to shut down BioPharma Dive

Opinion: dealing with failure, iTeos style | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Opinion: dealing with failure, iTeos style | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

iTeos To Close Down After TIGIT Fail - BioSpace

iTeos To Close Down After TIGIT Fail BioSpace

iTeos, reeling from TIGIT fail, becomes latest prize for deal-hungry Concentra - Fierce Biotech

iTeos, reeling from TIGIT fail, becomes latest prize for deal-hungry Concentra Fierce Biotech

iTeos Therapeutics Enters into Agreement to Be Acquired by - GlobeNewswire

iTeos Therapeutics Enters into Agreement to Be Acquired by GlobeNewswire

iTeos to shut down following $2bn GSK-partnered TIGIT asset failure - Pharmaceutical Technology

iTeos to shut down following $2bn GSK-partnered TIGIT asset failure Pharmaceutical Technology

iTeos Therapeutics accepts takeover bid from Concentra - The Pharma Letter

iTeos Therapeutics accepts takeover bid from Concentra The Pharma Letter

ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders - Business Wire

ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders Business Wire

Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy - Clinical Trials Arena

Inupadenant “deprioritised” by iTeos in favour of pipeline TIGIT therapy Clinical Trials Arena

iTeos Therapeutics To Be Acquired by Concentra Biosciences - citybiz

iTeos Therapeutics To Be Acquired by Concentra Biosciences citybiz

Concentra To Acquire ITeos - Nasdaq

Concentra To Acquire ITeos Nasdaq

Concentra Buys Beleaguered iTeos at Slight Discount - BioSpace

Concentra Buys Beleaguered iTeos at Slight Discount BioSpace

iTeos to shut down operations after TIGIT setback and GSK exit - The Pharma Letter

iTeos to shut down operations after TIGIT setback and GSK exit The Pharma Letter

Walloon biotech iTeos to cease operations – 133 jobs at risk - The Brussels Times

Walloon biotech iTeos to cease operations – 133 jobs at risk The Brussels Times

GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs - Fierce Biotech

GSK axes $625M TIGIT drug as midphase data disappoint, promoting partner iTeos to cut costs Fierce Biotech

iTeos to Present Preclinical Data on Potential - GlobeNewswire

iTeos to Present Preclinical Data on Potential GlobeNewswire

TIGIT drug from iTeos shrinks lung tumors in trial - BioPharma Dive

TIGIT drug from iTeos shrinks lung tumors in trial BioPharma Dive

iTeos, GSK to shelve TIGIT drug after study setback - BioPharma Dive

iTeos, GSK to shelve TIGIT drug after study setback BioPharma Dive

Adios, iTeos: Biotech folds weeks after GSK TIGIT termination - Fierce Biotech

Adios, iTeos: Biotech folds weeks after GSK TIGIT termination Fierce Biotech

Belrestotug Program Terminated After Mixed Phase 2 Results in NSCLC - Targeted Oncology

Belrestotug Program Terminated After Mixed Phase 2 Results in NSCLC Targeted Oncology

Another TIGIT bites the dust | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Another TIGIT bites the dust | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire

iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire

iTeos deprioritizes cancer candidate despite 'encouraging' phase 2 data - Fierce Biotech

iTeos deprioritizes cancer candidate despite 'encouraging' phase 2 data Fierce Biotech

GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC - BioSpace

GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC BioSpace

GSK, iTeos to develop cancer drug in up to $2 bln deal - Reuters

GSK, iTeos to develop cancer drug in up to $2 bln deal Reuters

Cancer Pipelines Shrink as Incyte, iTeos Cut Candidates Following Disappointing Data - BioSpace

Cancer Pipelines Shrink as Incyte, iTeos Cut Candidates Following Disappointing Data BioSpace

Concentra deals piling up as struggling biotechs look for options - BioCentury

Concentra deals piling up as struggling biotechs look for options BioCentury

iTeos Therapeutics to wind down operations, explore asset sales - Investing.com

iTeos Therapeutics to wind down operations, explore asset sales Investing.com

ESMO: iTeos-GSK's TIGIT star shows meaningful improvement - Fierce Biotech

ESMO: iTeos-GSK's TIGIT star shows meaningful improvement Fierce Biotech

iTeos Therapeutics stock price target lowered to $10 at Leerink Partners - Investing.com

iTeos Therapeutics stock price target lowered to $10 at Leerink Partners Investing.com

iTeos Therapeutics Winds Down Operations: Key Assets EOS-984 and EOS-215 Up for Sale - Stock Titan

iTeos Therapeutics Winds Down Operations: Key Assets EOS-984 and EOS-215 Up for Sale Stock Titan

TIGITs Trend Upward After iTeos/GSK Present Positive Data at ESMO - BioSpace

TIGITs Trend Upward After iTeos/GSK Present Positive Data at ESMO BioSpace

iTeos Therapeutics Announces Merger with Concentra Biosciences - TipRanks

iTeos Therapeutics Announces Merger with Concentra Biosciences TipRanks

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA, CORZ, ITOS, VBTX on Behalf of Shareholders - PR Newswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates STAA, CORZ, ITOS, VBTX on Behalf of Shareholders PR Newswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, ZIMV, XAGE on Behalf of Shareholders - PR Newswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, ZIMV, XAGE on Behalf of Shareholders PR Newswire

iTeos Therapeutics and GSK announce development and - GlobeNewswire

iTeos Therapeutics and GSK announce development and GlobeNewswire

GSK pays iTeos $625M upfront to join Merck, Roche and the rest in TIGIT immuno-oncology race - Fierce Biotech

GSK pays iTeos $625M upfront to join Merck, Roche and the rest in TIGIT immuno-oncology race Fierce Biotech

iTeos eyes $100m initial public offering - - Global Venturing

iTeos eyes $100m initial public offering - Global Venturing

6 Dimensions supports $125m round for iTeos - - Global Venturing

6 Dimensions supports $125m round for iTeos - Global Venturing

iTeos Therapeutics (ITOS) Faces Downgrade Amid Operational Changes | ITOS Stock News - GuruFocus

iTeos Therapeutics (ITOS) Faces Downgrade Amid Operational Changes | ITOS Stock News GuruFocus

iTeos Therapeutics reports Q4 EPS (85c), consensus ($1.03) - TipRanks

iTeos Therapeutics reports Q4 EPS (85c), consensus ($1.03) TipRanks

To TIGIT or not to TIGIT? Roche's latest trial flop casts shadow on Big Pharma's $6B bet - Fierce Biotech

To TIGIT or not to TIGIT? Roche's latest trial flop casts shadow on Big Pharma's $6B bet Fierce Biotech

Annexon, Inozyme, iTeos snag $564M in upsized IPOs - Fierce Biotech

Annexon, Inozyme, iTeos snag $564M in upsized IPOs Fierce Biotech

Pfizer drops iTeos IDO1 cancer drug due to lack of efficacy - Fierce Biotech

Pfizer drops iTeos IDO1 cancer drug due to lack of efficacy Fierce Biotech

Pioneering the Future of Drug Discovery with AI and RNAi Technologies - Vox Markets

Pioneering the Future of Drug Discovery with AI and RNAi Technologies Vox Markets

Top Iteos Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant